慢性肾脏病患者高钾血症的发生、危险因素与临床结局:丹麦人群队列研究
CKD 3A、3B、4、5期患者第一年内高钾血症发生率分别为9%、18%、31%、42%。高钾血症与6个月内急性住院(HR 2.11)和死亡(HR 4.85)风险显著升高相关。
要点
- 超1/4新诊断CKD患者发生高钾血症,且随CKD分期加重而升高。
- 糖尿病、心衰、使用ACEI、补钾剂或螺内酯是高钾血症的重要危险因素。
- 高钾血症后6个月死亡风险显著增加(26% vs 6%),需加强监测。
核心结论
- 超过四分之一的CKD患者发生高钾血症,严重CKD、糖尿病、心衰或使用螺内酯者风险高。
- 高钾血症与严重临床结局相关,包括急性住院和死亡风险显著增加。
研究设计与样本
- 比较发生高钾血症的CKD患者与匹配的未发生高钾血症CKD患者的危险因素和临床结局。
主要发现
- 28%的CKD患者发生高钾血症,总发生率为70/1000人年。
- CKD 3A、3B、4、5期患者第一年内高钾血症发生率分别为9%、18%、31%、42%。
- 高钾血症的危险因素包括糖尿病(PR 1.74,95%CI 1.69-1.79)、心衰(PR 2.31,95%CI 2.23-2.40)、使用ACEI(PR 1.45,95%CI 1.42-1.48)、补钾剂(PR 1.59,95%CI 1.55-1.62)或螺内酯(PR 2.53,95%CI 2.44-2.63)。
- 高钾血症患者6个月内任何急性住院的风险比为2.11,其中心脏诊断HR 2.07、室性心律失常HR 2.29、心脏骤停HR 3.26、重症监护HR 4.77、死亡HR 4.85。
- 高钾血症后6个月死亡率为26%,匹配的非高钾血症患者为6%。
关键数值与推荐
- 高钾血症定义为首次血液检测血钾水平>5.0 mmol/L。
- CKD定义为第二次eGFR测量<60 mL/min/1.73 m2或医院诊断。
临床怎么用
- 对CKD患者,尤其是晚期CKD、合并糖尿病、心衰或使用螺内酯者,应定期监测血钾。
- 高钾血症发生后需警惕短期内急性住院和死亡风险升高,加强随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the true burden of hyperkalemia (HK) in patients with chronic kidney disease (CKD) in a real-world setting are scarce. METHODS: The incidence rate of HK [first blood test with an elevated blood potassium level level >5.0 mmol/L] in primary or hospital care was assessed in a population-based cohort of all newly diagnosed CKD patients [second estimated glomerular filtration rate (eGFR) measurement <60 mL/min/1.73 m2 or hospital diagnosis] in northern Denmark. Risk factors and clinical outcomes were compared for CKD patients with HK and matched CKD patients without HK. RESULTS: Of 157 766 patients with CKD, 28% experienced HK, for an overall HK incidence rate of 70/1000 person-years. Among patients with Stage 3A, 3B, 4 or 5 CKD, 9, 18, 31 and 42%, respectively, experienced HK within the first year. Important HK risk factors included diabetes {prevalence ratio [PR] 1.74 [95% confidence interval (CI) 1.69-1.79]}, heart failure [PR 2.31 (95% CI 2.23-2.40)] and use of angiotensin-converting enzyme inhibitors [PR 1.45 (95% CI 1.42-1.48)], potassium supplements [PR 1.59 (95% CI 1.55-1.62)] or spironolactone [PR 2.53 (95% CI 2.44-2.63)]. In CKD patients who developed HK, 34% had any acute hospitalization 6 months before the HK event, increasing to 57% 6 months after HK [before-after risk ratio 1.72 (95% CI 1.69-1.74)]. The 6-month mortality following HK was 26%, versus 6% in matched non-HK patients. Compared with non-HK patients, 6-month hazard ratios for any acute hospitalization in HK patients were 2.11-fold higher, including hazard ratios of 2.07 for cardiac diagnoses, 2.29 for ventricular arrhythmias, 3.26 for cardiac arrest, 4.77 for intensive care and 4.85 for death. CONCLUSIONS: More than one in four CKD patients develops HK. Patients with severe CKD, diabetes, heart failure or use of spironolactone are at high risk. HK is associated with severe clinical outcomes.
引用
- Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Nephrol Dial Transplant. 2018. PMID: 29177463. doi:10.1093/ndt/gfx312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。